Eli Lilly And Co (NYSE: LLY) announced the results of the CHALLENGE-MIG clinical trial of Emgality (galcanezumab-gnlm) and Nurtec ODT (rimegepant orally disintegrating tablet). Emgality did not meet the study's primary endpoint, defined as statistical superiority to Nurtec ODT on the percentage of participants achieving a 50% or greater reduction in monthly migraine headache days. Pfizer Inc (NYSE: PFE) added Nurtec ODT to its portfolio after it acquired Biohaven Pharmaceutical for $11.6 billion